Considering the pathophysiology of ABC-DLBCL, characterized by selective mutations to facilitate the chronically active BCR pathway, it was hypothesized that higher-risk patients with the ABC subtype may benefit from ibrutinib [27,32]. The gene discussed is BCR; the disease is diffuse large B-cell lymphoma.